Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Goodwill & Intangibles: 2017-2023

Historic Goodwill & Intangibles for Aclaris Therapeutics (ACRS) over the last 7 years, with Dec 2023 value amounting to $751,000.

  • Aclaris Therapeutics' Goodwill & Intangibles fell 89.82% to $751,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $751,000, marking a year-over-year decrease of 89.82%. This contributed to the annual value of $751,000 for FY2023, which is 89.82% down from last year.
  • According to the latest figures from FY2023, Aclaris Therapeutics' Goodwill & Intangibles is $751,000, which was down 89.82% from $7.4 million recorded in FY2022.
  • Aclaris Therapeutics' 5-year Goodwill & Intangibles high stood at $25.9 million for FY2019, and its period low was $751,000 during FY2023.
  • For the 3-year period, Aclaris Therapeutics' Goodwill & Intangibles averaged around $5.2 million, with its median value being $7.4 million (2022).
  • Data for Aclaris Therapeutics' Goodwill & Intangibles shows a maximum YoY tumbled of 89.82% (in 2023) over the last 5 years.
  • Aclaris Therapeutics' Goodwill & Intangibles (Yearly) stood at $25.9 million in 2019, then slumped by 71.49% to $7.4 million in 2020, then remained steady at $7.4 million in 2021, then remained steady at $7.4 million in 2022, then plummeted by 89.82% to $751,000 in 2023.